Delivery Order SPE2DB22D2005-SPE2DB24FJEE7
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $184,789.80 firm fixed-price delivery order contract is for the supply of Biktarvy 50-200-25 mg tablets. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $27,217.56, is for the delivery of the drug Biktarvy 50-200-25 mg tablet. It is a firm fixed-price delivery order contract, with an ultimate completion date of December 6, 2021. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company and subsidiary of Cencora, Inc. The contract, valued at $144,534.13, is a delivery order for the supply of Biktarvy 50-200-25 mg tablets. It has a completion date of December 12, 2022 and is a firm fixed-price contract. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp holds a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,200.61 delivery order is for the supply of Biktarvy 50-200-25 mg tablets, a specialty medication. The contract has an ultimate completion date of March 24, 2022. Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a critical vendor for federal healthcare programs, particularly within military and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $31,340.78, is a delivery order for Biktarvy 50-200-25 mg tablet with an ultimate completion date of March 1, 2024. The contract is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen's parent company, Cencora, Inc., and the DLA Troop Support Medical, valued at up to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $10,704.06 firm fixed-price delivery order is for the supply of Biktarvy 50-200-25 mg tablets. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which provides a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Biktarvy 50-200-25 mg tablets. The contract, valued at $5,927.58, is a firm-fixed-price delivery order with a completion date of September 19, 2023. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $7,018.10, is for the delivery of Biktarvy 50-200-25 mg tablets. The contract is a firm fixed-price Delivery Order with an ultimate completion date of January 26, 2022. The contract is not designated with a set-aside requirement, indicating it was awarded through full and open competition....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $148,403.49 firm fixed-price delivery order is for Biktarvy 50-200-25 mg tablet (NDC 4564491911), with a completion date of May 6, 2024. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. This IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $6,243.36 firm fixed-price delivery order is for the supply of Biktarvy 50-200-25 mg tablets, a prescription medication. The contract has an ultimate completion date of May 28, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB24FJEE7Delivery Order
This federal contract award is a delivery order from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $33,900.29 firm fixed-price contract is for the delivery of Biktarvy 50-200-25 mg tablet units, with a performance period ending on October 19, 2023. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies, particularly the Department of Defense and Department of Veterans Affairs healthcare systems. The company holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for delivering a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.9k | 10/18/23 |